268 related articles for article (PubMed ID: 32117045)
21. Pharmacological management of acromegaly: a current perspective.
Manjila S; Wu OC; Khan FR; Khan MM; Arafah BM; Selman WR
Neurosurg Focus; 2010 Oct; 29(4):E14. PubMed ID: 20887124
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics, pharmacodynamics, and safety of pasireotide LAR in patients with acromegaly: a randomized, multicenter, open-label, phase I study.
Petersenn S; Bollerslev J; Arafat AM; Schopohl J; Serri O; Katznelson L; Lasher J; Hughes G; Hu K; Shen G; Reséndiz KH; Giannone V; Beckers A
J Clin Pharmacol; 2014 Nov; 54(11):1308-17. PubMed ID: 24800725
[TBL] [Abstract][Full Text] [Related]
23. Long-term Efficacy and Safety of Pasireotide in Patients With Acromegaly: 14 Years of Single-Center Real-World Experience.
Gadelha M; Marques NV; Fialho C; Scaf C; Lamback E; Antunes X; Santos E; Magalhães J; Wildemberg LE
J Clin Endocrinol Metab; 2023 Nov; 108(12):e1571-e1579. PubMed ID: 37357993
[TBL] [Abstract][Full Text] [Related]
24. Real-world experience with pasireotide-LAR in resistant acromegaly: a single center 1-year observation.
Stelmachowska-Banaś M; Czajka-Oraniec I; Tomasik A; Zgliczyński W
Pituitary; 2022 Feb; 25(1):180-190. PubMed ID: 34498217
[TBL] [Abstract][Full Text] [Related]
25. Pasireotide in an insulin-requiring diabetic acromegalic patient without worsening of hyperglycemia.
Gordon MB; Spiller KL
Endocrinol Diabetes Metab Case Rep; 2017; 2017():. PubMed ID: 28567297
[TBL] [Abstract][Full Text] [Related]
26. De-escalation treatment with pasireotide for acromegaly: a long-term experience.
Giampietro A; Menotti S; Chiloiro S; Pontecorvi A; De Marinis L; Bianchi A
Endocrine; 2023 Jun; 80(3):505-510. PubMed ID: 36808072
[TBL] [Abstract][Full Text] [Related]
27. Safety and efficacy of oral octreotide in acromegaly: results of a multicenter phase III trial.
Melmed S; Popovic V; Bidlingmaier M; Mercado M; van der Lely AJ; Biermasz N; Bolanowski M; Coculescu M; Schopohl J; Racz K; Glaser B; Goth M; Greenman Y; Trainer P; Mezosi E; Shimon I; Giustina A; Korbonits M; Bronstein MD; Kleinberg D; Teichman S; Gliko-Kabir I; Mamluk R; Haviv A; Strasburger C
J Clin Endocrinol Metab; 2015 Apr; 100(4):1699-708. PubMed ID: 25664604
[TBL] [Abstract][Full Text] [Related]
28. Long-term efficacy and safety of once-monthly pasireotide in Cushing's disease: A Phase III extension study.
Fleseriu M; Petersenn S; Biller BMK; Kadioglu P; De Block C; T'Sjoen G; Vantyghem MC; Tauchmanova L; Wojna J; Roughton M; Lacroix A; Newell-Price J
Clin Endocrinol (Oxf); 2019 Dec; 91(6):776-785. PubMed ID: 31465533
[TBL] [Abstract][Full Text] [Related]
29. AIP-mutated acromegaly resistant to first-generation somatostatin analogs: long-term control with pasireotide LAR in two patients.
Daly AF; Rostomyan L; Betea D; Bonneville JF; Villa C; Pellegata NS; Waser B; Reubi JC; Waeber Stephan C; Christ E; Beckers A
Endocr Connect; 2019 Apr; 8(4):367-377. PubMed ID: 30851160
[TBL] [Abstract][Full Text] [Related]
30. ACROBAT Edge: Safety and Efficacy of Switching Injected SRLs to Oral Paltusotine in Patients With Acromegaly.
Gadelha MR; Gordon MB; Doknic M; Mezősi E; Tóth M; Randeva H; Marmon T; Jochelson T; Luo R; Monahan M; Madan A; Ferrara-Cook C; Struthers RS; Krasner A
J Clin Endocrinol Metab; 2023 Apr; 108(5):e148-e159. PubMed ID: 36353760
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial.
Lacroix A; Gu F; Gallardo W; Pivonello R; Yu Y; Witek P; Boscaro M; Salvatori R; Yamada M; Tauchmanova L; Roughton M; Ravichandran S; Petersenn S; Biller BMK; Newell-Price J;
Lancet Diabetes Endocrinol; 2018 Jan; 6(1):17-26. PubMed ID: 29032078
[TBL] [Abstract][Full Text] [Related]
32. Predictive factors and the management of hyperglycemia in patients with acromegaly and Cushing's disease receiving pasireotide treatment:
Feldt-Rasmussen U; Bolanowski M; Zhang SL; Yu Y; Witek P; Kalra P; Kietsiriroje N; Piacentini A; Pedroncelli AM; Samson SL
Front Endocrinol (Lausanne); 2024; 15():1250822. PubMed ID: 38577574
[TBL] [Abstract][Full Text] [Related]
33. Pasireotide in Acromegaly: A Review.
McKeage K
Drugs; 2015 Jun; 75(9):1039-48. PubMed ID: 26017304
[TBL] [Abstract][Full Text] [Related]
34. Biochemical efficacy of long-acting lanreotide depot/Autogel in patients with acromegaly naïve to somatostatin-receptor ligands: analysis of three multicenter clinical trials.
Alquraini H; Del Pilar Schneider M; Mirakhur B; Barkan A
Pituitary; 2018 Jun; 21(3):283-289. PubMed ID: 29357081
[TBL] [Abstract][Full Text] [Related]
35. Serial follow-up of presurgical treatment using pasireotide long-acting release with or without octreotide long-acting release for naïve active acromegaly.
Chang JS; Tseng HM; Chang TC
J Formos Med Assoc; 2016 Jun; 115(6):475-80. PubMed ID: 27117887
[TBL] [Abstract][Full Text] [Related]
36. Safety and Efficacy of Subcutaneous Pasireotide in Patients With Cushing's Disease: Results From an Open-Label, Multicenter, Single-Arm, Multinational, Expanded-Access Study.
Fleseriu M; Iweha C; Salgado L; Mazzuco TL; Campigotto F; Maamari R; Limumpornpetch P
Front Endocrinol (Lausanne); 2019; 10():436. PubMed ID: 31379734
[No Abstract] [Full Text] [Related]
37. Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing's disease: results from an open-ended, open-label extension trial.
Schopohl J; Gu F; Rubens R; Van Gaal L; Bertherat J; Ligueros-Saylan M; Trovato A; Hughes G; Salgado LR; Boscaro M; Pivonello R;
Pituitary; 2015 Oct; 18(5):604-12. PubMed ID: 25537481
[TBL] [Abstract][Full Text] [Related]
38. Pasireotide Long-Acting Release Treatment for Diabetic Cats with Underlying Hypersomatotropism.
Gostelow R; Scudder C; Keyte S; Forcada Y; Fowkes RC; Schmid HA; Church DB; Niessen SJ
J Vet Intern Med; 2017 Mar; 31(2):355-364. PubMed ID: 28145031
[TBL] [Abstract][Full Text] [Related]
39. Systematic dose-extension of octreotide LAR: the importance of individual tailoring of treatment in patients with acromegaly.
Turner HE; Thornton-Jones VA; Wass JA
Clin Endocrinol (Oxf); 2004 Aug; 61(2):224-31. PubMed ID: 15272918
[TBL] [Abstract][Full Text] [Related]
40. Impact of preoperative pasireotide therapy on invasive octreotide-resistant acromegaly.
Yamamoto R; Robert Shima K; Igawa H; Kaikoi Y; Sasagawa Y; Hayashi Y; Inoshita N; Fukuoka H; Takahashi Y; Takamura T
Endocr J; 2018 Oct; 65(10):1061-1067. PubMed ID: 30078825
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
